Private Equity

Private equity funds investing in life sciences face a dynamic and complex landscape. They must evaluate opportunities across Pharma, Biotech, MedTech, Diagnostics, and HealthTech, balancing scientific innovation, commercial potential, regulatory hurdles, and geopolitical considerations such as trade restrictions, cross-border investments, and global regulatory divergence. Investment decisions require rigorous assessment of portfolio companies’ strategic positioning, operational efficiency, and growth potential, alongside careful risk management in a sector characterized by long R&D cycles, evolving technology, and shifting reimbursement landscapes. PE investors focus on operational value creation, leveraging data-driven insights, digital transformation, and targeted M&A to accelerate growth and maximize returns. Competitive dynamics, patent cliffs, biosimilar penetration, and evolving market access policies further complicate investment theses, making deep sector expertise and actionable intelligence critical for successful outcomes.

We execute Commercial Due Diligences (CDD) with a sector-specific lens, assessing pipeline potential, market dynamics, competitive positioning, pricing and reimbursement frameworks, and adoption prospects across geographies and care settings. Our analysis identifies key growth levers, operational constraints, and strategic opportunities, enabling investors to make confident, high-impact decisions. Complementing this, we conduct Vendor Due Diligences (VDD) to prepare portfolio companies for sale or capital raises, ensuring that commercial, operational, and strategic information is structured, validated, and presented in a transparent, credible way to prospective buyers.

Beyond due diligence, we support build-up strategies, helping PE-backed companies identify, evaluate, and integrate complementary acquisitions. Our approach combines market screening, synergy quantification, target prioritization, and integration planning to accelerate growth, expand capabilities, and capture scale advantages. We also provide hands-on support with post-merger integration (PMI), aligning commercial, R&D, and operational functions, defining governance frameworks, and establishing performance metrics to ensure synergies are realized and strategic objectives are delivered.

Across all M&A and transaction activities, we leverage deep life sciences expertise, practical commercial insight, and operational know-how to deliver actionable recommendations. Whether supporting buy-side evaluation, sell-side preparation, or platform growth initiatives, we help PE funds make faster, more informed decisions, reduce execution risk, and maximize returns in a complex, regulated, and competitive industry.